FDA to revise labeling of ADHD medication to indicate weight loss risk

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain formulations of amphetamine and methylphenidate, to warn about the medication’s risk for weight loss and other adverse reactions in patients younger than 6 years of age.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup